CANDLE Syndrome — Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature, a proteasome-associated autoinflammatory syndrome (PRAAS) caused by mutations affecting proteasomal subunits and proteasome assembly chaperones, most commonly autosomal recessive loss-of-function mutations in PSMB8 (proteasome subunit beta type 8, encoding the immunoproteasome-specific LMP7 catalytic subunit), with compound heterozygous and digenic mutations also described in PSMA3, PSMB4, PSMB9, POMP, and other proteasome-associated genes, resulting in impaired immunoproteasome assembly and catalytic activity that causes accumulation of ubiquitinated and oxidized protein aggregates in cells — particularly in neutrophils and plasmacytoid dendritic cells — triggering a type I interferon-driven inflammatory response through TBK1/IRF3 activation, with ISG scores markedly elevated analogous to other type I interferonopathies; CANDLE syndrome presents in infancy with daily, debilitating recurrent fever — temperatures of 39–41°C occurring every 1–4 weeks and lasting days, sometimes with partial response to corticosteroids but rarely complete suppression — accompanied by the pathognomonic annular erythematous to violaceous nodular skin plaques that undergo central clearing to produce ring-shaped (annular) lesions with purpuric centers and expanding erythematous borders, most prominent on the trunk, face, and proximal extremities, and histologically showing an atypical, dense neutrophilic and mononuclear dermal infiltrate that is neither a classic Sweet syndrome nor a leukocytoclastic vasculitis but the characteristic CANDLE dermal inflammatory pattern; a progressive, disfiguring lipodystrophy — loss of subcutaneous fat primarily in the face (resulting in a prematurely aged, hollow-cheeked appearance), extremities, and trunk — that worsens over years with metabolic consequences including insulin resistance, hypertriglyceridemia, and fatty liver despite the patient's lean body habitus; an inflammatory myopathy with muscle weakness, elevated CK and aldolase, and myopathic changes on muscle MRI; and systemic features including periorbital edema, joint contractures, failure to thrive in infancy, growth impairment, basal ganglia calcifications in PSMB8-associated cases, and laboratory abnormalities including markedly elevated CRP, ESR, ferritin, LDH, and transaminases reflecting multi-organ inflammatory involvement; treatment is with JAK inhibitors — baricitinib (approved by the FDA in 2023 for CANDLE syndrome and other PRAAS conditions as the first approved therapy for PRAAS) and ruxolitinib as alternative or salvage — which suppress the type I interferon and cytokine-driven inflammation through JAK1/2-STAT1/3 pathway inhibition, reducing fever frequency, ISG scores, skin plaque burden, and inflammatory markers, though the lipodystrophy and some damage accrual are not fully reversible; monitoring digital health platforms for CANDLE must coordinate immunoproteasome genetic diagnosis, type I interferon signature surveillance, body composition imaging for lipodystrophy tracking, metabolic complication management, inflammatory myopathy monitoring, and JAK inhibitor safety across a patient population so rare that fewer than 100 cases are described globally.
CANDLE syndrome technology platforms — encompassing the pediatric rheumatology and autoinflammatory rare disease specialty platforms where the fever-annular plaques-lipodystrophy triad raises the PRAAS/CANDLE diagnosis and proteasome gene panel testing is initiated, the genetic testing platforms where PSMB8, PSMA3, PSMB4, PSMB9, and POMP mutation analysis confirms the diagnosis, the immunology laboratory platforms measuring ISG scores and IFN-α levels that serve as CANDLE disease activity biomarkers and baricitinib response markers, the dermatology platforms managing the annular skin plaques and lipodystrophy progression including photographic documentation, lesion mapping, and dermal biopsy coordination, the body composition and lipodystrophy surveillance platforms including whole-body DXA scanning for regional adipose tissue quantification, MRI-based subcutaneous fat volume measurement, and body composition software tracking the lipodystrophy trajectory, the metabolic medicine platforms managing the insulin resistance, hypertriglyceridemia, and fatty liver that complicate the lipodystrophy — including fasting glucose, HbA1c, insulin level, lipid panel, and liver ultrasound or elastography platforms, the rheumatology and physical therapy platforms managing joint contractures and inflammatory myopathy, the JAK inhibitor management platforms coordinating baricitinib or ruxolitinib prescribing, CBC and metabolic monitoring, infection prophylaxis, and ISG score response documentation, and the multidisciplinary CANDLE coordination platforms aligning pediatric rheumatology, dermatology, metabolic medicine, genetics, physical therapy, and neurology — must maintain the availability and performance standards required by the PRAAS genetic diagnosis precision, ISG score monitoring demands, lipodystrophy surveillance intensity, metabolic complication management complexity, and JAK inhibitor safety monitoring obligations that define modern CANDLE syndrome care. This guide explains why CANDLE syndrome tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the proteasome gene panel confirmation, ISG score tracking, body composition imaging, metabolic complication surveillance, and baricitinib response documentation that define modern CANDLE care.
Why CANDLE Syndrome Tech Platforms Require Specialized Monitoring Attention
CANDLE syndrome management is defined by several uniquely complex PRAAS management dimensions: the diagnostic complexity — the CANDLE phenotype overlaps with Nakajo-Nishimura syndrome, JMP syndrome, and other PRAAS, all caused by mutations in overlapping sets of proteasome and assembly chaperone genes, requiring comprehensive proteasome gene panel sequencing or whole exome sequencing to establish the specific molecular diagnosis; the type I interferon monitoring precision — ISG score measurements performed at specialized immunology reference laboratories serve as both CANDLE diagnostic confirmation and baricitinib dose adequacy biomarkers, analogous to their role in SAVI; the lipodystrophy surveillance complexity — progressive regional loss of subcutaneous fat tracked by DXA scanning and MRI requires specialized body composition imaging platforms not standard in most hospital systems; the metabolic complication management — insulin resistance, hypertriglyceridemia, and non-alcoholic fatty liver disease as consequences of lipodystrophy require regular metabolic laboratory platforms and imaging platforms; and the JAK inhibitor safety in a pediatric population — baricitinib approved for CANDLE in pediatric patients requires age-appropriate dosing, regular CBC surveillance, and infection risk management including PCP prophylaxis.
Proteasome gene panel platforms confirm the PRAAS molecular diagnosis. The identification of biallelic pathogenic variants in PSMB8, PSMA3, PSMB4, PSMB9, POMP, or compound heterozygous or digenic mutations in proteasome-associated genes by NGS PRAAS gene panel or whole exome sequencing establishes the CANDLE diagnosis and identifies the specific immunoproteasome subunit deficit. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
ISG score platforms are the CANDLE disease activity and baricitinib response biomarker. Serial Interferon Scores quantifying peripheral blood ISG transcript levels confirm CANDLE diagnosis, guide baricitinib initiation, and document dose adequacy and treatment response over time. Monitor ISG score platforms at 1-minute intervals during laboratory hours.
Body composition imaging platforms track the defining lipodystrophy. Whole-body DXA scanning for regional fat mass quantification and MRI-based subcutaneous fat volume measurement document the lipodystrophy progression that is the most visible disease manifestation and a metabolic complication driver. Monitor body composition imaging platforms at 1-minute intervals during radiology operational hours.
Metabolic medicine platforms manage insulin resistance and hypertriglyceridemia. Fasting glucose, HbA1c, insulin, lipid panel, and liver function platforms monitor the metabolic consequences of lipodystrophy that increase cardiovascular and hepatic risk in CANDLE patients. Monitor metabolic platforms at 1-minute intervals during clinical and laboratory hours.
Baricitinib management platforms coordinate the approved PRAAS therapy. Dose titration, weekly-to-monthly CBC surveillance during dose escalation, LFT and lipid monitoring, PCP prophylaxis prescribing, and ISG score response documentation require reliable platform availability throughout the treatment course. Monitor baricitinib management platforms at 1-minute intervals during clinical hours.
Inflammatory myopathy platforms monitor muscle disease. CK and aldolase levels, muscle MRI, and physical therapy function assessment document the myopathic component of CANDLE syndrome and guide physical therapy intensity and corticosteroid adjunct use. Monitor myopathy platforms at 1-minute intervals during clinical and radiology hours.
What to Monitor on a CANDLE Syndrome Tech Platform
Genetic Testing — Proteasome Gene Panel Analysis
Monitor genetic testing referral records (clinical suspicion documentation — daily or near-daily fever beginning in infancy, annular erythematous-violaceous skin plaques with pathognomonic histology, progressive lipodystrophy in face and extremities, elevated CRP and ferritin, elevated ISG score, myopathy, joint contractures, family history of similar presentation, consanguinity), PRAAS proteasome gene panel records (NGS panel including PSMB8, PSMA3, PSMB4, PSMB9, POMP, and other immunoproteasome assembly gene sequencing and deletion/duplication analysis — biallelic pathogenic variant identification, compound heterozygous mutation detection, digenic mutation identification in combined deficiency), whole exome sequencing records (WES for cases where targeted panel is uninformative — novel gene identification, compound heterozygous detection across all exons), functional proteasome activity assay records (chymotrypsin-like, trypsin-like, and caspase-like proteasomal catalytic activity measured in patient-derived PBMCs — reduced LMP7-associated chymotrypsin-like activity confirming immunoproteasome insufficiency for novel variants), genotype-phenotype correlation records (PSMB8 mutations associated with basal ganglia calcifications; POMP mutations associated with more skin-predominant phenotype), and genetic counseling records (autosomal recessive inheritance, carrier testing for parents, predictive testing for siblings) at 1-minute intervals during laboratory hours. Alert immediately — proteasome gene panel result delays in an 18-month-old who has had daily fever since 3 months of age and is developing progressive facial fat loss with ring-shaped skin plaques prolong the diagnostic odyssey and defer baricitinib initiation during ongoing systemic inflammation, lipodystrophy accrual, and potential joint contracture development.
Interferon Signature — ISG Score and IFN-α Monitoring
Monitor ISG score assay records (Interferon Score by NanoString nCounter, Fluidigm BioMark, or RT-PCR quantification of ISG15, IFIT1, IFIT2, IFIT3, RSAD2, and SIGLEC1 transcript levels — ISG scores greater than 2 standard deviations above healthy control mean confirming type I interferonopathy; magnitude correlating with disease activity severity), serial ISG score trajectory records (at diagnosis and monthly during baricitinib dose escalation, then quarterly at stable dose — the primary biomarker for baricitinib dose adequacy), SIMOA IFN-α quantification records (serum IFN-α by single molecule array — markedly elevated in active CANDLE, declining with effective baricitinib), CXCL10 records (interferon-inducible IP-10 as a complementary and more widely available interferon-response biomarker), ISG score normalization records (complete versus partial ISG score suppression on baricitinib — complete normalization associated with better fever, skin, and growth outcomes; partial normalization prompting dose escalation or ruxolitinib addition), and IFN-α level-to-ISG score correlation records (cross-platform biomarker validation supporting dose escalation decisions) at 1-minute intervals during laboratory hours. Alert immediately — ISG score platform failures when a 5-year-old CANDLE patient on baricitinib 2 mg/day has a quarterly ISG score check pending that will determine whether the current dose is providing complete interferon suppression or whether escalation to 4 mg/day is required to prevent further lipodystrophy and contracture accrual leave the primary disease activity biomarker unavailable for the dose adequacy decision.
Body Composition — Lipodystrophy Surveillance
Monitor whole-body DXA records (dual-energy X-ray absorptiometry scanning at baseline and annually — regional fat mass quantification: face/head, arms, trunk, legs, android/gynoid regions; lean mass; bone mineral density; fat-free mass index; body fat percentage; comparison to age- and sex-matched normative data to quantify lipodystrophy extent), MRI-based fat volume records (MRI T1 sequence for subcutaneous fat volume quantification at face, extremities, and trunk — volumetric fat measurement for lipodystrophy staging and JAK inhibitor response assessment), body composition analysis software records (3D fat volume reconstruction and fat distribution mapping — lipodystrophy stage scoring), and anthropometric records (serial triceps and subscapular skinfold thickness, mid-arm circumference, and waist circumference documenting lipodystrophy trajectory between formal imaging studies) at 1-minute intervals during radiology operational hours. Alert on sustained failures — body composition imaging platform failures delay the annual DXA lipodystrophy staging for a 10-year-old CANDLE patient on baricitinib, interrupting the fat mass trajectory documentation that demonstrates whether baricitinib has stabilized or continues to lose facial fat.
Metabolic Medicine — Insulin Resistance and Dyslipidemia
Monitor fasting glucose records (quarterly fasting glucose — insulin resistance screening; impaired fasting glucose greater than 100 mg/dL triggering formal OGTT), fasting insulin and HOMA-IR records (insulin resistance quantification — HOMA-IR above 2.5 in prepubertal patients triggering metabolic medicine consultation), HbA1c records (quarterly glycated hemoglobin — pre-diabetes greater than 5.7% and diabetes greater than 6.5% triggering endocrinology referral and metformin consideration), fasting lipid panel records (total cholesterol, LDL, HDL, triglycerides — hypertriglyceridemia above 500 mg/dL triggering fibrate therapy; LDL elevation assessment; baricitinib-associated lipid effects), liver function records (AST, ALT, alkaline phosphatase, GGT at quarterly intervals — transaminase elevation both from CANDLE inflammatory myopathy and from baricitinib hepatotoxicity monitoring; steatohepatitis surveillance), liver ultrasound or elastography records (annual hepatic ultrasound for fatty liver assessment; FibroScan for hepatic stiffness in patients with chronic transaminase elevation), and metformin or lipid-lowering therapy management records (prescribing, adherence, metabolic response documentation) at 1-minute intervals during clinical and laboratory hours. Alert immediately — fasting glucose monitoring platform failures in a 13-year-old CANDLE patient with lipodystrophy and a HOMA-IR of 3.8 from 6 months ago who requires quarterly glucose monitoring prevent the detection of new pre-diabetes that would trigger endocrinology referral and dietary intervention before frank diabetes develops.
Inflammatory Myopathy — CK, Aldolase, and Muscle Imaging
Monitor CK records (serum creatinine kinase at quarterly intervals — CK elevation above 3x ULN documenting active inflammatory myopathy; CK trajectory under baricitinib), aldolase records (aldolase as a complementary muscle enzyme marker — sensitive for inflammatory myopathy and more reflective of disease activity in some CANDLE patients than CK), muscle MRI records (T1 and STIR muscle MRI at affected muscle groups — fat replacement on T1 indicating chronic myopathic damage; muscle edema on STIR indicating active inflammation; muscle volume quantification for atrophy progression), physical therapy function assessment records (grip strength, 6-minute walk distance, timed up-and-go test, functional mobility assessment documenting myopathy impact on daily function), and joint contracture documentation records (passive range of motion measurement at large and small joints — elbow, knee, finger joint contractures quantified and mapped; physiotherapy intervention records for contracture prevention and management) at 1-minute intervals during clinical and radiology operational hours. Alert on sustained failures — muscle MRI platform failures delay the annual inflammatory myopathy staging for a 16-year-old CANDLE patient with elbow flexion contractures, interrupting the STIR edema versus T1 fatty replacement assessment that determines whether active anti-inflammatory therapy intensification or contracture-focused physiotherapy is the priority.
Baricitinib Therapy Management
Monitor baricitinib prescribing and dispensing records (weight-based pediatric dosing — baricitinib 2 mg/day for patients 10–<30 kg and 4 mg/day for patients ≥30 kg in the PRAAS approval; dose escalation records; pharmacy dispensing confirmation; missed dose alerts), CBC monitoring records (weekly during first month of therapy and at dose escalation, monthly thereafter — neutropenia grade 1-2 requiring dose reduction; thrombocytopenia; lymphopenia; anemia surveillance), LFT and lipid records (AST, ALT, total cholesterol, LDL, HDL, triglycerides at baseline and quarterly — baricitinib-associated transaminase elevation and lipid perturbation monitoring), renal function records (creatinine at baseline and quarterly — baricitinib renal elimination requiring dose adjustment for GFR <60 mL/min), PCP prophylaxis records (trimethoprim-sulfamethoxazole prescribing and adherence documentation — mandatory during baricitinib therapy in pediatric patients), herpes zoster risk management records (VZV serostatus at baseline; varicella vaccination completion or contraindication documentation; acyclovir or valacyclovir prophylaxis in VZV-seropositive patients), and infection surveillance records (bacterial, opportunistic, and herpes family virus infection documentation during baricitinib therapy) at 1-minute intervals during clinical hours. Alert immediately — CBC monitoring platform failures in an 8-year-old CANDLE patient on baricitinib 2 mg/day during the first month of therapy, when weekly CBC is required for dose-escalation neutropenia monitoring, leave the dose-escalation safety check without the neutrophil count result that must confirm ANC above 1,000/μL before the next dose increase.
Dermatology — Annular Plaque Documentation
Monitor annular plaque lesion documentation records (lesion location — trunk, face, proximal extremities; lesion diameter; violaceous versus erythematous border color; central clearing pattern; purpuric center documentation; standardized photographic documentation at quarterly intervals), skin biopsy records (biopsy of active plaque histology — dense atypical neutrophilic and mononuclear dermal infiltrate, nuclear debris, absence of vasculitis; pathognomonic CANDLE pattern versus Sweet syndrome versus leukocytoclastic vasculitis differential documentation), plaque burden scoring records (total body surface area involvement, lesion count, severity score — CANDLE plaque response to baricitinib quantified as percentage BSA reduction from baseline), and periorbital edema records (periorbital puffiness grading — a CANDLE disease activity marker responsive to baricitinib) at 1-minute intervals during clinical hours. Alert on sustained failures — dermatology documentation platform failures delay the quarterly plaque burden score update that confirms baricitinib is providing meaningful skin disease suppression before the annual ISG score check.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. CANDLE syndrome management coordinates across pediatric rheumatology and autoinflammatory specialties (proteasome gene diagnosis, baricitinib initiation), clinical immunology (ISG score monitoring, IFN-α quantification), dermatology (annular plaque documentation, skin biopsy coordination), metabolic medicine and endocrinology (insulin resistance, lipid management, fatty liver), body composition radiology (DXA, MRI fat quantification), genetics (proteasome gene panel, carrier testing), physical therapy and rehabilitation (contracture management, myopathy), neurology (basal ganglia calcification surveillance), pharmacy (baricitinib dispensing, PCP prophylaxis), infectious disease (opportunistic infection surveillance), and international PRAAS research coordination — authentication failures block every team member required to execute the ISG score monitoring, body composition surveillance, metabolic complication management, and JAK inhibitor safety monitoring that define CANDLE care.
SSL Certificates
Monitor SSL certificate expiry across all genetic testing platforms, ISG score laboratory portals, body composition imaging systems, metabolic medicine platforms, baricitinib management systems, dermatology documentation portals, and PRAAS registry platforms. Certificate errors disrupt ISG score result transmission (most critically, since baricitinib dose decisions depend on this), body composition imaging scheduling, and metabolic monitoring workflows.
HIPAA and Ultra-Rare PRAAS Patient Privacy Considerations
CANDLE syndrome technology platforms handle highly sensitive PHI for one of the rarest autoinflammatory diseases described — with fewer than 100 confirmed patients globally — in a population where the visible disease manifestations (progressive lipodystrophy causing facial fat loss, annular skin plaques, joint contractures) are highly distinctive and may identify patients visually within their communities. Records include proteasome gene panel molecular testing (autosomal recessive heritable mutations with implications for siblings and family members), ISG score measurements at specialized immunology reference laboratories, body composition DXA and MRI data documenting progressive lipodystrophy, metabolic complication records including insulin resistance and hypertriglyceridemia, muscle MRI, and baricitinib prescribing in pediatric patients under the PRAAS indication.
The heritable nature of PSMB8 and related proteasome gene pathogenic variants creates genetic information privacy obligations under GINA and HIPAA Privacy Rule requirements, with heightened community re-identification risk given the extreme rarity of the diagnosis and the visible phenotype. For baricitinib management platforms coordinating the only FDA-approved CANDLE therapy — where platform unavailability delays the weekly CBC check that determines neutropenia risk during dose escalation in a pediatric patient — availability monitoring provides documentation relevant to HIPAA Security Rule compliance and the urgent safety obligations of JAK inhibitor therapy in children.
Alerting Strategy for CANDLE Syndrome Tech Platforms
Immediate clinical-hours alerting for baricitinib management platforms: Weekly CBC during dose escalation, LFT and lipid monitoring, PCP prophylaxis documentation, and ISG score response tracking. Pediatric JAK inhibitor safety monitoring cannot tolerate undetected platform outages during the critical early weeks of dose escalation.
Immediate laboratory-hours alerting for ISG score and interferon signature platforms: ISG score, SIMOA IFN-α, and CXCL10. These are the disease activity biomarkers that drive baricitinib dose titration decisions.
Immediate laboratory-hours alerting for genetic testing platforms: PRAAS proteasome gene panel and whole exome sequencing. Diagnostic delays in CANDLE extend the pre-treatment interval during which lipodystrophy, joint contractures, and myopathy accrue irreversibly.
Immediate laboratory-hours alerting for metabolic monitoring platforms: Fasting glucose, HbA1c, insulin, lipid panel, and LFT. Lipodystrophy-driven insulin resistance and dyslipidemia require regular metabolic surveillance.
Immediate radiology-hours alerting for body composition imaging: DXA whole-body fat quantification and MRI subcutaneous fat volume measurement.
Immediate clinical and radiology-hours alerting for inflammatory myopathy platforms: CK, aldolase, and muscle MRI.
Sustained-failure alert (10–15 minutes): PRAAS registry, genetic counseling coordination, dermatology biopsy scheduling, and neurology platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms CANDLE syndrome platform availability from the geographies where PRAAS autoinflammatory centers of excellence, proteasome gene molecular testing programs, and baricitinib specialty pharmacy networks concentrate — including specialized centers at the NIH, in France, Germany, Japan, and the United Kingdom.
Status Page for CANDLE Syndrome Care Team Communication
A real-time status page gives pediatric rheumatologists managing baricitinib therapy, clinical immunologists monitoring ISG scores and IFN-α levels, dermatologists documenting annular plaque burden, metabolic medicine specialists managing insulin resistance and dyslipidemia, body composition radiologists quantifying lipodystrophy by DXA and MRI, physical therapists managing joint contractures and myopathy, geneticists confirming proteasome gene panel variants, specialty pharmacists managing baricitinib dispensing, and PRAAS registry coordinators immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in baricitinib dose escalation protocols (so clinicians know when CBC platform availability is reduced during weekly dose escalation safety checks), ISG score laboratory emergency procedures, and PSMB8 proteasome gene panel laboratory emergency procedures.
Vigilmon Setup for CANDLE Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | ISG score (NanoString / RT-PCR panel) | 1 min | Slack + PagerDuty (lab hours) | | SIMOA IFN-α quantification | 1 min | Slack + PagerDuty (lab hours) | | CXCL10 / IP-10 (interferon-inducible chemokine) | 1 min | Slack + PagerDuty (lab hours) | | PRAAS proteasome gene panel (PSMB8, PSMA3, PSMB4, PSMB9, POMP) | 1 min | Slack + PagerDuty (lab hours) | | Whole exome sequencing (novel gene detection) | 1 min | Slack + PagerDuty (lab hours) | | Baricitinib prescribing and dose escalation records | 1 min | Slack + PagerDuty (clinical hours) | | Weekly CBC (neutropenia during dose escalation) | 1 min | Slack + PagerDuty (lab hours) | | LFT and lipid monitoring (baricitinib safety) | 1 min | Slack + PagerDuty (lab hours) | | PCP prophylaxis (TMP-SMX prescribing and adherence) | 1 min | Slack + PagerDuty (clinical hours) | | Fasting glucose, HbA1c, insulin (insulin resistance) | 1 min | Slack + PagerDuty (lab hours) | | Fasting lipid panel (hypertriglyceridemia, LDL) | 1 min | Slack + PagerDuty (lab hours) | | Liver function and hepatic ultrasound / elastography | 1 min | Slack + PagerDuty (lab/radiology hours) | | Whole-body DXA (regional fat mass, lipodystrophy staging) | 1 min | Slack + PagerDuty (radiology hours) | | MRI subcutaneous fat volume (lipodystrophy) | 1 min | Slack + PagerDuty (radiology hours) | | CK and aldolase (inflammatory myopathy) | 1 min | Slack + PagerDuty (lab hours) | | Muscle MRI (STIR edema vs T1 fatty replacement) | 2 min | Slack + PagerDuty (radiology hours) | | Annular plaque documentation and dermatology biopsy | 1 min | Slack (clinical hours) | | Joint contracture ROM measurement (PT records) | 2 min | Slack (clinical hours) | | PRAAS autoinflammatory registry and clinical trial access | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure ISG score platforms with immediate laboratory-hours alerting — the CANDLE disease activity biomarker and baricitinib dose adequacy metric
- Add SIMOA IFN-α quantification with immediate laboratory-hours alerting
- Configure CXCL10/IP-10 monitoring with immediate laboratory-hours alerting
- Add PRAAS proteasome gene panel platforms with immediate laboratory-hours alerting
- Configure whole exome sequencing platforms with immediate laboratory-hours alerting
- Add baricitinib prescribing and dose escalation platforms with immediate clinical-hours alerting
- Configure weekly CBC (dose escalation safety) with immediate laboratory-hours alerting
- Add LFT and lipid monitoring with immediate laboratory-hours alerting
- Configure PCP prophylaxis prescribing and adherence with immediate clinical-hours alerting
- Add fasting glucose, HbA1c, and insulin platforms with immediate laboratory-hours alerting
- Configure fasting lipid panel monitoring with immediate laboratory-hours alerting
- Add liver function and hepatic imaging platforms with immediate alerting during operational hours
- Configure whole-body DXA platforms with immediate radiology-hours alerting
- Add MRI subcutaneous fat volume platforms with immediate radiology-hours alerting
- Configure CK and aldolase monitoring with immediate laboratory-hours alerting
- Add muscle MRI platforms with sustained-failure alerting during radiology hours
- Configure annular plaque documentation with immediate clinical-hours alerting
- Add joint contracture and physical therapy function platforms with sustained-failure alerting
- Configure PRAAS registry with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to baricitinib dose escalation protocols, ISG score laboratory emergency procedures, and PSMB8 gene panel laboratory emergency procedures
Conclusion
CANDLE syndrome technology platforms are embedded in clinical decisions where ISG score platform availability when a 7-year-old CANDLE patient on baricitinib 2 mg/day has a quarterly ISG score check that will determine whether the current dose is achieving complete type I interferon suppression — when the ISG score must return normal or near-normal values confirming baricitinib adequacy before the next DXA body composition scan documents whether lipodystrophy has stabilized or whether dose escalation to 4 mg/day is needed to halt ongoing adipose tissue loss — cannot be disrupted by ISG score platform failures that eliminate the biomarker data that should precede both the dose decision and the body composition imaging; where DXA body composition platform availability for a 12-year-old CANDLE patient whose annual whole-body DXA is scheduled to quantify whether the face and arm fat mass has stabilized on baricitinib compared to the prior year's scan — when the endocrinologist, rheumatologist, and metabolic medicine team need the current fat mass quantification data to confirm that baricitinib is protecting against further lipodystrophy accrual and that insulin resistance is not worsening as facial fat continues to be lost — cannot be disrupted by DXA scheduling platform failures that defer the body composition measurement that anchors the multi-disciplinary management decision; and where baricitinib management platform availability when a 9-year-old CANDLE patient is in the first month of baricitinib treatment and requires weekly CBC to confirm neutrophil count safety before each dose increase — when the pediatric rheumatologist must see an ANC above 1,000/μL before authorizing the next week's dose escalation step in the titration protocol — cannot be disrupted by CBC monitoring platform failures that leave the dose escalation safety check without the laboratory data required to proceed. An ISG score platform unavailable when baricitinib dose adequacy must be quantified, a DXA platform unavailable when lipodystrophy trajectory must document that JAK inhibition is providing protection, a baricitinib CBC safety check platform unavailable during first-month dose escalation in a pediatric patient — these are not IT incidents. They are clinical disruptions in the management of one of the rarest and most complex autoinflammatory syndromes in medicine, whose immunoproteasome deficiency, type I interferonopathy, progressive lipodystrophy, metabolic complications, and inflammatory myopathy demand ISG score precision, body composition surveillance continuity, metabolic monitoring regularity, and baricitinib safety monitoring reliability that can only be guaranteed by dedicated platform monitoring.
Uptime monitoring gives CANDLE syndrome tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to PRAAS autoinflammatory syndrome centers of excellence, clinical immunology ISG score reference laboratories, body composition radiology programs, proteasome gene molecular testing services, metabolic medicine and endocrinology programs, specialty pharmacies managing baricitinib for the PRAAS indication, and compliance auditors that platform operational reliability matches the ISG score monitoring precision, body composition surveillance intensity, metabolic complication management demands, and JAK inhibitor safety obligations of modern CANDLE syndrome care.
Start monitoring your CANDLE syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #CANDLE #syndrome #PRAAS #proteasome #PSMB8 #PSMA3 #lipodystrophy #interferonopathy #type1 #interferon #ISG #score #baricitinib #JAK #inhibitor #annular #plaques #myopathy #insulin #resistance #DXA #body #composition #autoinflammatory #rare #disease #HIPAA #healthtech #digitalhealth #uptime #sre